Matthew Painschab, MD (IMAGE)
Caption
UNC LIneberger's Matthew Painschab, MD, and colleagues report in Lancet Global Health that they have demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective.
Credit
UNC School of Medicine
Usage Restrictions
None
License
Licensed content